Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02823405
Title Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors X4 Pharmaceuticals
Indications

melanoma

Therapies

Pembrolizumab + X4P-001

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.